Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
- Trial name
- NCT06456567
- Testing
- Telitacicept
- Where
- 4 sites in United States
- Sponsor
- Vor Biopharma
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Systemic Lupus Erythematosus
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
- Trial name
- NCT05123586
- Testing
- LY3361237
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain…
- Conditions
- Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
- Trial name
- NCT07281105
- Testing
- EG-501
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Evergreen Therapeutics, Inc.
Systemic Lupus Erythematosus
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs.
- Trial name
- NCT05638802
- Testing
- DS-7011a
- Where
- 20 sites in United States, China and 2 more
- Volunteers
- 26 people
- Sponsor
- Daiichi Sankyo
Systemic Lupus Erythematosus
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
- Trial name
- NCT00774943
- Testing
- AMG 557
- Where
- 12 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus, Healthy
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
The purpose of this study is to assess the safety and tolerability of JNJ-55920839 following single ascending intravenous (IV) dose administration in healthy participants and a single subcutaneous dose in healthy participants and…
- Trial name
- NCT02609789
- Testing
- JNJ-55920839
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Lupus Nephritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants.
- Trial name
- NCT01085097
- Testing
- Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 46 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Systemic Lupus Erythematosus
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.
- Trial name
- LUPIL-2 (NCT02955615)
- Testing
- ILT-101
- Where
- 25 sites in Austria, Bulgaria and 8 more
- Volunteers
- 100 people
- Sponsor
- Iltoo Pharma
Lupus Nephritis
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
The study will investigate the efficacy and safety of enteric-coated mycophenolate sodium in combination with two different corticosteroid (CS) regimes for the induction of remission of a lupus nephritis flare.
- Trial name
- NCT00423098
- Testing
- Mycophenolate sodium, Prednisone, Methylprednisolone
- Where
- 17 sites in Colombia, France and 7 more
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint…
- Trial name
- NCT07607964
- Testing
- ABBV-519
- Where
- 15 sites in United States, Japan
- Volunteers
- 30 people
- Sponsor
- AbbVie
Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- TOPAZ-1 (NCT04895241)
- Testing
- Litifilimab
- Where
- 164 sites in United States, Australia and 13 more
- Volunteers
- 548 people
- Sponsor
- Biogen
Systemic Lupus Erythematosus
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- BLISS-SC (NCT01484496)
- Testing
- Belimumab 200 mg SC, Standard therapy
- Where
- 207 sites in United States, Argentina and 29 more
- Volunteers
- 839 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Trial name
- NCT07089121
- Testing
- Descartes-08
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cartesian Therapeutics
Systemic Lupus Erythematosus
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.
- Trial name
- NCT05203692
- Testing
- DS-7011a
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
- Trial name
- NCT06625671
- Testing
- DB-2304, Prednisone
- Where
- 7 sites in United States, Australia
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- DualityBio Inc.
Lupus Nephritis
Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis
The purpose of conducting phase 1 trial to evaluate the safety and tolerability of allogenic bone marrow-derived mesenchymal stem cells(CS20AT04) in subjects with lupus nephritis.
- Trial name
- NCT03174587
- Testing
- allogenic bone marrow derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Corestemchemon, Inc.
Systemic Lupus Erythematosus
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
- Trial name
- NCT02660944
- Testing
- RSLV-132
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Resolve Therapeutics
Systemic Lupus Erythematosus
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. All subjects will receive 4 weekly doses of study drug over a 3 week period, and then will be followed for an additional 28 weeks, for…
- Trial name
- NCT02411136
- Testing
- AMG 623
- Volunteers
- 64 people
- Sponsor
- Amgen